News Releases

Director of LICR Oxford Branch, Professor Xin Lu, PhD FRCPath, Elected to European Molecular Biology Organization

LICR is pleased to announce that Professor Xin Lu PhD FRCPath, Director of the Oxford Branch, has been elected as a member of the European Molecular Biology Organization (EMBO). EMBO is an organization of over 1,500 leading life scientists that fosters new generations of researchers to produce world-class scientific results, and helps to shape science and research policy by seeking feedback from its community of members. Professor Lu has been recognized along with more than 40 other outstanding scientists from around the world in 2011, for her proven excellence in research.

Professor Lu joined the LICR’s London Branch in 1993 as an Assistant Member, after a postdoctoral post in Sir David Lane’s lab in Dundee. She was progressively promoted to LICR Full Member in 2000, during which time she made major contributions to the understanding of cross-regulation between the p53 and Rb pathways, identifying how alterations in the Rb pathway could sensitize tumor cells to p53-induced apoptosis. Since then, she has conducted pioneering work leading to the discovery and characterization of the ASPP family of proteins, which plays a key role in modulating the cell’s response to p53. In 2004, she was appointed Director of the LICR’s London Branch but moved the unit to Oxford in 2007, where she created the Oxford Branch which is focused on the identification of molecular switches that drive cancer progression and cellular heterogeneity, with the aim of benefiting patients.

Congratulations to Professor Lu for her exceptional achievement.

Other LICR members of EMBO include Drs. Colin Goding (Oxford Branch), Thierry Boon (Brussels Branch), Carl-Henrik Heldin (Uppsala Branch) and Thomas Perlmann (Stockholm Branch); former Branch Directors Drs. Ralf Pettersson (Stockholm Branch) and Michael Waterfield (London Branch); and former LICR London Branch investigators Drs. Anne Ridley and Bart Vanhaesebroeck.


You are now leaving Ludwig Cancer Research's website and are going to a website that is not operated by the association. We are not responsible for the content or availability of linked sites. Do you wish to continue?